Pharmacological treatment of psoriatic arthritis: A systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis

Annals of the Rheumatic Diseases

Volumn 75, Issue 3, 2016, Pages 490-498

  Ramiro, Sofia ^a   Smolen, Josef S ^b   Landewé, Robert ^c   Van Der Heijde, Désirée ^a   Dougados, Maxime ^d,e   Emery, Paul ^f,g   De Wit, Maarten ^h   Cutolo, Maurizio ⁱ   Oliver, Susan ^j   Gossec, Laure ^k,l  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Zuyderland Medical Centre   (Netherlands)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Institut Cochin   (France)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^h People with Arthritis Rheumatism in Europe (PARE)   (United Kingdom)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j Independent Nurse Consultant   (United Kingdom)

^k SORBONNE UNIVERSITÉ   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; APREMILAST; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; SECUKINUMAB; USTEKINUMAB; ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; DACTYLITIS; DIARRHEA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTHESITIS; FUNCTIONAL DISEASE; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ARTHRITIS, PSORIATIC; PRACTICE GUIDELINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; GLUCOCORTICOIDS; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84960193219     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208466     Document Type: Article

References (51)

1. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780-9.
2. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9.
3. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020-6.
4. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137-46.
5. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med 2015;373:1329-39.
6. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
7. Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510.
8. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319-26.
9. Sackett D, WS R, Rosenberg W, et al. Evidence-based medicine: how to practice and teach EBM. London: Churchill Livingstone, 1997.
10. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 2014;73:3-5.
11. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48-53.
12. Higgins J, Altman DA. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Chapter 8. The Cochrane Collaboration, 2008.
13. Deeks JH, Altman D. Analysing data and undertaking meta-analyses: Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
14. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012;51:1368-77.
15. Atzeni F, Boccassini L, Antivalle M, et al. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis 2011;70:712-14.
16. Asaduzzaman ATM, Sikder A, Mahmud MM, et al. Efficacy and safety of leflunomide in psoriatic arthritis. J Pakistan Assoc Dermatol 2014;24:51-6.
17. Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012;64:2504-17.
18. Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). J Rheumatol Suppl 2012;89:90-3.
19. Kavanaugh A, McInnes IB, Krueger GG, et al. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2013;65:1666-73.
20. Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013;72:1777-85.
21. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 2014;73:1689-94.
22. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:48-55.
23. Gladman D, Fleischmann R, Coteur G, et al. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res (Hoboken) 2014;66:1085-92.
24. van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis 2014;73:233-7.
25. Kavanaugh A, Gladman D, van der Heijde D, et al. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Ann Rheum Dis 2015;74:44-51.
26. Kavanaugh A, Gladman D, van der Heijde D. Reduction of disease burden on workplace and household productivity in psoriatic arthritis over 48 weeks of treatment with certolizumab pegol. Arthritis Rheum 2013;65(Suppl 10):326.
27. Kavanaugh A, Gladman D, van der Heijde D. Sustained improvements in workplace and household productivity and social participation with certolizumab pegol over 96 weeks in patients with psoriatic arthritis. Arthritis Rheum 2014;66(Suppl 10):1552.
28. Baranauskaite A, Raffayová H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 2012;71:541-8.
29. Mease PJ, Heckaman M, Kary S, et al. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol 2013;40:647-52.
30. Sterry W, Ortonne J-P, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147.
31. Prinz JC, Fitzgerald O, Boggs RI, et al. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. J Eur Acad Dermatol Venereol 2011;25:559-64.
32. Gniadecki R, Robertson D, Molta CT, et al. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 2012;26:1436-43.
33. Boggs RL, Karpáti S, Li W, et al. Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment. BMC Dermatol 2014;14:14.
34. Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014;73:1000-6.
35. Zhang F, Tencer T, Li S. Work productivity improvement associated with apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial. Arthritis Rheum 2014;66(Suppl 10):1597.
36. Kavanaugh A, Adebajo AO, Gladman DD. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial. Arthritis Rheum 2014;66(Suppl 10):1590.
37. Mease PJ, Adebajo AO, Gladman DD. Long-Term (104-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial and Open-Label Extension. Arthritis Rheum 2014;66(Suppl 10):1564.
38. Cutolo M, Myerson G, Fleischmann R. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2). Arthritis Rheum 2013;65 (Suppl 10):815.
39. Edwards C, Blanco FJ, Crowley J. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3). Arthritis Rheum 2013;65(Suppl 10):311.
40. Wells A, Edwards C, Adebajo AO. Apremilast in the treatment of DMARD-Naïve psoriatic arthritis patients: results of a phase 3 randomized, controlled trial (PALACE 4). Arthritis Rheum 2013;65(Suppl 10):L4.
41. Wells A, Aelion JA, Adebajo AO. A phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, for treatment of psoriatic arthritis: long-term (52-week) improvements in physical function. Arthritis Rheum 2014;66 (Suppl 10):602.
42. Adebajo AO, Wells A, Edwards C. Long-term safety and tolerabiility of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: a phase 3, randomized, controlled trial. Ann Rheum Dis 2014;73(Suppl 2):730.
43. Wells A, Edwards C, Adebajo AO. Long-term (104-week) safety and efficacy of monotherapy with apremilast in dmard-naïve patients with psoriatic arthritis: a phase 3, randomized, controlled trial and open-label extension (PALACE 4). Arthritis Rheum 2014;66(Suppl 10):L22.
44. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015. doi: 10.1016/S0140-6736(15)00347-5. [Epub ahead of print 30 Sep 2015].
45. Kavanaugh A, Puig L, Gottlieb AB. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 2-year results from a phase 3, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 2013;65(Suppl 10):L10.
46. Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol 2015;14:706-14.
47. Palominos PE, Gaujoux-Viala C, Fautrel B, et al. Clinical outcomes in psoriatic arthritis: A systematic literature review. Arthritis Care Res (Hoboken) 2012;64:397-406.
48. Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167-70.
49. Tillett W, Eder L, Goel N, et al. Enhanced patient involvement and the need to revise the core set-report from the psoriatic arthritis working group at OMERACT 2014. J Rheumatol 2015;42:2198-203.
50. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
51. Smolen JS, Weinblatt ME. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? Ann Rheum Dis 2008; 67:1497-8.